A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2018
At a glance
- Drugs MK-7252 (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 20 Jul 2018 Status changed from active, no longer recruiting to recruiting.
- 04 Jul 2018 Planned End Date changed from 22 Jul 2018 to 13 Dec 2018.
- 04 Jul 2018 Planned primary completion date changed from 22 Jul 2018 to 13 Dec 2018.